|
DISCLOSURE INFORMATION
The Disclosure Policy of Projects In KnowledgeSM requires that faculty participating in a CME activity disclose to the audience any significant relationship they may have with a pharmaceutical or medical equipment company, product, or service that may be mentioned as part of their presentation, as well as any relationship with the commercial supporter of this activity.
This independent CME activity is supported by an unrestricted educational grant from 
This activity may include a discussion of therapies that are unapproved for use or investigational, ongoing research, or preliminary data.
The opinions expressed during this activity are those of the faculty and do not necessarily reflect those of the sponsor or the commercial supporter.
PRESENTER DISCLOSURES
Clifford A. Brass, MD, PhD, is an employee of Integrated Therapeutics Group Inc., a Schering subsidiary.
Douglas T. Dieterich, MD, has indicated a significant relationship with the following companies: Schering-Plough, Roche, Gilead Sciences, Glaxo Wellcome, and Bristol-Myers Squibb.
Eliot W. Godofsky, MD, has indicated a significant relationship with the following company: Schering-Plough.
Ira M. Jacobson, MD, has indicated a significant relationship with the following companies: Schering, Glaxo Wellcome, and Roche.
Christine Johnsen, MPH, NP, has indicated no significant relationships.
Sherilyn Laughton, CRNP, has indicated no significant relationships.
Michele A. Mays, ARNP, has indicated no significant relationships.
Barbara H. McGovern, MD, has indicated a significant relationship with the following companies: Schering and Roche.
Richard B. Pollard, MD, has indicated a significant relationship with Abbott Laboratories, Agouron Pharmaceuticals, Inc, Boehringer Ingelheim Pharmaceuticals, Inc, Bristol-Myers Squibb Company, DuPont Pharmaceuticals Company, Glaxo Wellcome Inc, Hoffman-LaRoche, and Triangle Pharmaceuticals, Inc.
Fredric Regenstein, MD, has indicated a significant relationship with the following companies: Roche and Schering-Plough.
Charles M. Rice, PhD, has indicated a significant relationship with the following companies: AlphaVax Human Vaccines, Inc, Apath, LLC, CANVAC, Eli Lilly and Company, and ViroPharm Incorporated.
Marcel F. Srur, MD, has indicated no significant relationships.
Glenn J. Treisman, MD, PhD, has indicated no significant relationships.
Karen B. Weisz, MN, CFNP, has not specified any significant relationship with industry.
Ian T. Williams, PhD, MS, has indicated no significant relationships.
CONTRIBUTING FACULTY DISCLOSURES
Daniel F. Alvarez-Arnao, MD, has received grant/research support from Glaxo Wellcome Inc; and is a member of the speakers bureaus for Glaxo Wellcome Inc and Ortho Biotech Inc.
Joseph Baran, Jr, MD, has not specified any significant relationships with industry.
Murray D. Batt, MD, is a consultant for Bayer Corporation and Glaxo Wellcome Inc; is a member of the speakers bureau for Pfizer Inc; and does educational meeting support for Agouron Pharmaceuticals, Inc, Pharmacia & Upjohn and Schering Corporation.
Marye Bernard, MSN, FNP, has not specified any significant relationships with industry.
Francis X. Blais, DO, has not specified any significant relationships with industry.
Maurizio Bonacini, MD, has received grant/research support from Roche Pharmaceuticals and Schering Corporation and is a member of the speakers bureaus for Boehringer-Ingelheim Pharmaceuticals and Schering Corporation.
Susan E. Boruchoff, MD, has received grant/research support from Triangle-Clinical Trial.
Robert L. Brandt, Jr, MD, is a member of the speakers bureaus for and is an advisory group member for Abbott Laboratories Inc, Bristol-Myers Squibb Company, DuPont Pharmaceuticals, and Glaxo Wellcome Inc.
Edwin Brown, MD, has not specified any significant relationships with industry.
Damaris C. Carriero, NP-C, has not specified any significant relationships with industry.
Cinda Clark, APN, PhD, has received grant/research support from Schering-Plough Corporation and is a member of the speakers bureau for the University of Texas.
Susan Cournoyer, MSN, ANP-C, has not specified any significant relationships with industry.
Laura M. Dean, MSN, CRNP, is a member of the speakers bureaus for Agouron Pharmaceuticals, Inc, Bristol-Myers Squibb Company, GlaxoSmithKline, and Ortho Biotech Inc.
Mark Dougherty, MD, has not specified any significant relationships with industry.
Linda M. Durand, MSN, RNC, is a member of the speakers bureau for Schering Hepatitis Innovations.
Henry Gonzàlez-Rivera, MD, is a member of the speakers bureau for Schering-Plough Corporation.
Frances M. Homeyer, RN, MN, FNP-C, has not specified any significant relationships with industry.
Marc Johnson, MD, is a consultant for Agouron Pharmaceuticals Inc. and Roche Pharmaceuticals; and is a member of the speakers bureaus for Abbott Laboratories Inc, Agouron Pharmaceuticals, Inc, Bristol-Myers Squibb Company, Glaxo Wellcome Inc, Merck Laboratories, and Roche Pharmaceuticals.
Raymond M. Johnson, MD, PhD, has not specified any significant relationships with industry.
Gina Khraish, MD, has not specified any significant relationships with industry.
Daniel Kluger, MD, has not specified any significant relationships with industry.
Julia A. Kovacs, MD, has not specified any significant relationships with industry.
Stacy Kreiswirth, NP, has not specified any significant relationships with industry.
Pardeep Kumari, MD, has not specified any significant relationships with industry.
Margarita Lamothe, MD, has not specified any significant relationships with industry.
Juan S. Latorre, MD, has not specified any significant relationships with industry.
Carroll B. Leevy, MD, has received grant/research support from and is a consultant for Roche Pharmaceuticals and Schering Corporation; and is a member of the speakers bureaus for Glaxo Wellcome Inc, Janssen Pharmaceutica Inc, Roche Pharmaceuticals, Schering Corporation, and TAP Pharmaceuticals Inc.
James M. Levin is a member of the speakers bureaus for Bristol-Myers Squibb Company, Roche Pharmaceuticals Inc, and Schering Corporation.
Michael L. Levin, MD, is a member of the speakers bureau for Schering Hepatitis Innovations.
Cheryl D. Levine, PhD, FNP, has received grant/research support from Schering Corporation.
Chien Liu, MD, has not specified any significant relationships with industry.
Tom Madhavan, MD, has received research support from Aventis and Pharmacia & Upjohn; and is a member of the speakers bureaus for Aventis, Ortho-McNeil Pharmaceutical, Pfizer Inc, and Wyeth-Ayerst Pharmaceuticals.
Maureen Maliszewski, NP, has not specified any significant relationships with industry.
Lorenzo D. McKnelly, DO, has not specified any significant relationships with industry.
Connie McMahan, NP, has not specified any significant relationships with industry.
Dennis J. Mikolich, MD, has received research support from Roche Laboratories and Schering-Plough Corporation.
Danielle F. Milano, MD, is a member of the speakers bureaus for Ortho Biotech Inc and Schering Corporation.
Naiel N. Nassar, MD, has not specified any significant relationships with industry.
Cheryl Newman, MD, has received grant/research from DuPont Pharmaceuticals, Glaxo Wellcome Inc, Ortho Biotech Inc, Pfizer Inc, and Schering Corporation; and is a member of the speakers bureaus for Dupont Pharmaceuticals and Glaxo Wellcome Inc.
Catherine A. Olczak, FNP-CS, has not specified any significant relationships with industry.
Tanci C. Payne, CRNP, MSN, has not specified any significant relationships with industry.
Raymon Ramirez, MD, has not specified any significant relationships with industry.
Stephen A. Renae, MD, has not specified any significant relationships with industry.
Miguel J. Rodriguez, MD, has not specified any significant relationships with industry.
Rolando E. Saenz, MD, has not specified any significant relationships with industry.
Nael Shahatto, MD, is a member of the speakers bureau for Glaxo Wellcome Inc.
David G. Sidebottom, MD, is a member of the speakers bureaus for Abbott Laboratories Inc, Glaxo Wellcome Inc, Pfizer Inc, Roche Pharmaceuticals, and Ortho-McNeil Pharmaceutical.
Bentley Smith, MD, has not specified any significant relationships with industry.
Roxann Stubbs, MD, has not specified any significant relationships with industry.
Lavinia Suciu, MD, has not specified any significant relationships with industry.
Mary W. Thornton, CFNP, has received grant/research support from and is on the speakers bureau for Schering Corporation.
Bonnie Tiemann, NP, has not specified any significant relationships with industry.
Michele Till, MD, has received grant/research support from Agouron Pharmaceuticals, Inc and Pfizer Inc; and is on the speakers bureaus for Agouron Pharmaceuticals, Inc, and SmithKline Beecham Pharmaceuticals.
Sharon Valenti, MSN, RNCS, has not specified any significant relationships with industry.
Belinda Velazquez, MD, has not specified any significant relationships with industry.
|